Spots Global Cancer Trial Database for Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
Official Title: Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
Study ID: NCT03258047
Conditions
Interventions
Study Description
Brief Summary: It's a single arm, open label prospective study, in which the safety and efficacy of autologous CAR-T are evaluated in refractory/relapsed B cell lymphoma patients. Abbreviation: CAR-T: Chimeric Antigen Receptor T-Cell Immunotherapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The first affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
